Although these studies have not utilized the preclinical models of CM-induced ICP, the results from AQP4-deficient mice and stroke models suggest the potential utility of targeting AQP4 to reduce ICP in CM patients as well. The gene discussed is AQP4; the disease is cutaneous mastocytosis.